Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story

At 2:31 p.m. ET on Nov. 4, the Dow was up 3.0% (1,552.12 points), the S&P 500 and Nasdaq each gained 1.8%, and the Nasdaq Biotechnology Index rose 2.1%; the article says the rally followed Tuesday’s U.S. elections. Recent drugmaker reports were largely positive: Amgen revenue rose 8% to $10.4B, Gilead raised its full-year product-sales outlook, and Vertex and Incyte raised guidance; Merck narrowed its sales range and lifted its midpoint. Pricing headwinds remain, including Amgen’s 14% lower Enbrel net selling price and Gilead’s disclosure that the Medicare price for Biktarvy takes effect Jan. 1, 2028.

Analysis

The session looks more like broad risk-on beta than confirmation that biotech fundamentals have re-rated: the index is near a 52-week high after a large year-over-year advance, so election-driven positioning can amplify both upside and reversals over days. Company-level quality differs. Gilead’s raised outlook is the cleaner near-term operating signal, but Biktarvy’s CMS price change is a known 2028 revenue risk, not a next-quarter catalyst. Amgen’s Enbrel disclosure shows why reported sales can mask price/volume deterioration; favorable deductions and inventory are not durable offsets to lower net price. Incyte’s guidance uplift also includes a sizable one-time CMS-related benefit, so assess recurring growth separately. Vertex has multiple potential catalysts, but prescription counts alone do not establish durable economics; verify persistence, net pricing and contribution after the Crinetics deal. Merck’s narrowing of guidance and WINREVAIR growth are supportive, while the report does not resolve longer-term product concentration risk. Over 1–3 months, earnings follow-through and regulatory outcomes matter more than the index chart; over 6–18 months, pricing exposure and pipeline diversification should increasingly differentiate returns.

Key Decisions for Investors

• Avoid chasing the broad biotech move at the open. Add exposure only on a pullback or after the index holds its breakout; a close back below the Oct. 30 high would weaken the momentum thesis.
• Consider a measured GILD-over-AMGN relative-value position: Gilead has the stronger near-term guidance signal, while Amgen’s Enbrel price/volume pressure is a durability concern. Reassess if Gilead trims outlook or Amgen demonstrates sustained underlying volume and pricing stabilization.
• Treat INCY’s guidance increase as lower-quality until excluding the one-time $246 million benefit still supports the growth case. Verify recurring Opzelura sales and CMS-related cash/rebate accounting before adding.
• For VRTX, keep the Nov. 30 regulatory date on the catalyst calendar, but verify the FDA docket and the asset/company attribution before trading it; track JOURNAVX repeat use and economics rather than prescription volume alone.